CD86 and B-cell chronic lymphocytic leukemia: The patient group with ≥1.72% CD86+ CLL cells (CD86high) had a significantly shorter time to first treatment than the CD86low (<1.72% CD86+ CLL cells) subgroup (log-rank p = 0.0044; median time to first treatment for CD86high = 63.7 months, for CD86low = not reached; Fig.5B).